Form D · Biotechnology

Exonics Therapeutics, Inc.

Watertown, MA · CIK 0001722820

Offering snapshot reported Nov 20, 2018 · SEC filing

Reported sold
$22M
Offering amount: $42M
Investors reported
2
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 7, 2017
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$11M$22MNov 20, 2017: $22,043,962.00Nov 20, 2017Nov 20, 2018: $22,043,962.00Nov 20, 2018

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 20, 2018Amendment$22,043,962$0vs Nov 20, 20172SEC filing
Nov 20, 2017Initial$22,043,962No comparison2SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-299113

Source: Form D, filed Nov 20, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
David Goeddel Director
Jesper Gromada Executive
Jeen Joo Kang Director
H. James Magee Executive
Roger Perlmutter Director
John Ripple Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
490 Arsenal Way Suite 110
Watertown, MA, 02472